Roche presented updated data confirming the Swiss drugmaker’s immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer.
The U.S. Food and Drug Administration approved Roche’s immunotherapy Tecentriq in combination with the Swiss drugmaker’s Avastin for the most common kind of liver cancer.
